New drug N-803 tested to boost CAR T-Cell success in lymphoma patients
NCT ID NCT07049432
First seen Nov 20, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This early-phase study aimed to see if the drug N-803 is safe and tolerable for adults with B-cell non-Hodgkin lymphoma who had already received CAR T-cell therapy. Participants had to have responded to CAR T treatment. The study was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.